Sihvo Sinikka, Hämäläinen Juha, Kiviruusu Olli, Pirkola Sami, Isometsä Erkki
STAKES, National Research and Development Centre for Welfare and Health, P.O. Box 220, 00531 Helsinki, Finland.
J Affect Disord. 2006 Nov;96(1-2):31-8. doi: 10.1016/j.jad.2006.05.009. Epub 2006 Jun 22.
Treatments for anxiety disorders in the general population are not widely investigated. We determined the proportion, type and determinants of treatment in the Finnish general population.
Within the Health 2000 Study, a representative sample (n = 6005) of adults (age > 30 years) were interviewed in 2000-2001 with the Composite International Diagnostic Interview (M-CIDI) to assess the presence of DSM-IV mental disorders during the preceding 12 months. Logistic regression models were used to examine factors influencing the type of treatment (pharmacotherapy and/or psychological treatment) and also the types of pharmacotherapy (antidepressants, anxiolytics, or sedatives and hypnotics) used for anxiety disorders.
For individuals with an anxiety disorder, 40% (95/229) currently used psychotropic medication, 23% (55/229) used antidepressants, 19% (44/229) anxiolytics and 17% (41/229) sedatives or hypnotics. Of those using health care services for mental health reasons (34%, 76/229), 80% (61/76) received pharmacotherapy. Only 45% (34/76) reported having psychological treatment, with few having more than 4 visits (27%, 20/76). Living in a semi-urban environment, retirement and high perceived disability increased the likelihood of pharmacotherapy-only treatment; higher education and comorbidity with mood disorders increased the likelihood of psychological treatment. General practitioners more often than psychiatrists provided pharmacotherapy treatment alone (67% vs. 34%, p < 0.05), particularly anxiolytics or sedatives.
Use of mental health services and psychological treatment were based on self-reports. No data on duration of pharmacotherapy was available.
Anxiety disorders remain largely untreated in the general population. Among those seeking treatment, pharmacotherapy predominates, whereas even brief psychotherapies are rare. Contrary to clinical guidelines, anxiolytics and sedatives are commonly used instead of antidepressants.
针对普通人群焦虑症的治疗尚未得到广泛研究。我们确定了芬兰普通人群中治疗的比例、类型及决定因素。
在“健康2000研究”中,于2000 - 2001年对一个具有代表性的成年人群样本(n = 6005,年龄>30岁)进行访谈,采用复合国际诊断访谈(M - CIDI)评估在过去12个月内是否存在DSM - IV精神障碍。使用逻辑回归模型来研究影响治疗类型(药物治疗和/或心理治疗)的因素,以及用于焦虑症的药物治疗类型(抗抑郁药、抗焦虑药或镇静催眠药)。
对于患有焦虑症的个体,40%(95/229)目前正在使用精神药物,23%(55/229)使用抗抑郁药,19%(44/229)使用抗焦虑药,17%(41/229)使用镇静催眠药。在因心理健康原因使用医疗服务的人群中(34%,76/229),80%(61/76)接受了药物治疗。只有45%(34/76)报告接受了心理治疗,很少有人接受超过4次治疗(27%,20/76)。生活在半城市环境、退休以及较高的感知残疾增加了仅接受药物治疗的可能性;高等教育以及与情绪障碍共病增加了接受心理治疗的可能性。全科医生比精神科医生更常单独提供药物治疗(67%对34%,p < 0.05),尤其是抗焦虑药或镇静催眠药。
心理健康服务的使用和心理治疗基于自我报告。没有关于药物治疗持续时间的数据。
普通人群中的焦虑症在很大程度上仍未得到治疗。在寻求治疗的人群中,药物治疗占主导,而即使是简短的心理治疗也很少见。与临床指南相反,抗焦虑药和镇静催眠药比抗抑郁药更常用。